«Although FDA approval is critically important for introducing a new screening test or algorithm, providers ultimately rely on guidance or guidelines to help them make the best decisions for their patients and
want to understand advantages, disadvantages and unknowns associated with a new screening approach,» said Huh, who is a senior scientist for the UAB Comprehensive
Cancer Center, Director of the UAB Division of
Gynecologic Oncology, and is also a board member for both the American Society for Colposcopy and Cervical Pathology and the Society of
Gynecologic Oncology.